Dose dense AC followed by T + trastuzumab — Competitive Intelligence Brief

Dose dense AC followed by T + trastuzumab (Dose dense AC followed by T + trastuzumab) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemotherapy regimen with monoclonal antibody. Area: Oncology.

marketed Chemotherapy regimen with monoclonal antibody HER2 receptor (trastuzumab component); DNA/microtubules (chemotherapy components) Oncology Small molecule

Target snapshot

Dose dense AC followed by T + trastuzumab (Dose dense AC followed by T + trastuzumab) — Agendia. This is a chemotherapy regimen combining dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab (Herceptin) to treat HER2-positive breast cancer by killing cancer cells and blocking HER2 signaling.

Comparator set (1 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Dose dense AC followed by T + trastuzumab TARGET	Dose dense AC followed by T + trastuzumab	Agendia	marketed	Chemotherapy regimen with monoclonal antibody	HER2 receptor (trastuzumab component); DNA/microtubules (chemotherapy components)
PTH followed by dose dense AC of FEC	PTH followed by dose dense AC of FEC	Agendia	marketed	Combination chemotherapy regimen with monoclonal antibody	HER2 receptor; microtubule; DNA (topoisomerase II)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemotherapy regimen with monoclonal antibody class)

1. Agendia · 1 drug in this class